Drug
Icp 723
Icp 723: highest development phase Phase 1/2, developed by InnoCare Pharma. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- InnoCare Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| ICP-723 NCT04685226 | Phase 1/2 | Solid Tumors |
| ICP-723 NCT05537987 | Phase 1 | Advanced Solid Tumors |
Latest
No recent events.
Follow Icp 723 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.